Drugs / Noradrenalin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06083948 | Dec 2023 → Dec 2027 expected | hypotensive disorder | University of Aarhus | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00370253 | Sep 2006 → Sep 2007 | hepatorenal syndrome | University of Turin, Italy | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03087669 | Feb 2017 → Mar 2020 | left ventricular failure | Sahlgrenska University Hospital | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT06615102 Comparator | Mar 2025 → Jan 2027 expected | vascular disorder | University of Münster | Recruiting | No outcome recorded |
| — | NCT04144465 Comparator | Nov 2019 → Oct 2023 | — | Suez Canal University | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Noradrenalin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00370253 ↗ |